###### Strengths and limitations of this study

-   We only selected clinical trials conducted from 1st of January to 31st December 2010 for this study.

-   <http://www.clinicaltrials.gov> was the only source for selection of clinical trials this study.

-   We might have missed other websites as source to identify registered clinical trials.

Introduction {#s1}
============

The drugs we use to treat any condition---from an innocuous cough to a life-threatening cancer---are the outcome of painstaking human clinical trials. These trials are the only way to credibly determine the safety and efficacy of drugs. Without trials, there is no way pharmaceutical research can advance to improve disease management and the very quality of life. Clinical trials are considered as a gold standard in the field of evidence-based medicine.[@R1] In recent years, there has been a clear shift in clinical trial sites from core developed countries like the USA and European countries to developing countries like India, China and South American countries.[@R2] This shift is related to challenges and opportunities like costs of trials, recruitment issues and regulatory challenges in developed versus developing countries.[@R3] Since the early 1990s, the growth in the number of people participating in and required for pharmaceutical clinical trials has been massive. The number of clinical trial investigators conducting multinational clinical trials (trials conducted in more than one country with the same protocol) in low-income settings increased 16-fold in the past decade.[@R3] Many of these new trials are being performed in geographical areas of political and economic instability and unprecedented healthcare crises and where subjects are readily accessible. Drug companies' apparent ease of accessibility to such areas has raised questions about the unequal social contexts in which research is being performed and about how conditions of inequality are at present facilitating a global proliferation of pharmaceutical drug trials. This increase brings with it social, legal and ethical implications, and among them are the major issue of how the benefits of this research are shared.[@R2] [@R6] [@R7] Our university contact partners from developing countries---India and South Africa---had shown interest in this research question as randomised controlled trials conducted in India and South Africa have not been comprehensively assessed, and there is no effort to determine whether this research has led to the availability of new drugs to the local population. We also feel this research question will benefit the clinical research environment in the respective countries. We therefore constructed a comprehensive database of randomised controlled trials in India and South Africa from 2005 to 2010 and evaluated whether this research has resulted in market approvals of new drugs.

Methods {#s2}
=======

Eligibility criteria {#s2a}
--------------------

We screened all multinational randomised controlled trials from <http://www.clinicaltrials.gov> conducted in the period from 1 January 2005 to 31 December 2010. Multinational trials that had trial sites in India and South Africa were selected for this study.

Identification of trials and new drug approvals {#s2b}
-----------------------------------------------

We searched the US trials registry of the National Institutes of Health, ClinicalTrials.gov, the main global trial registration site to identify clinical trials conducted by global sponsors in preselected developing countries, India and South Africa. We only selected the trials which were interventional, phase II and III, funded by industry, registered, conducted and completed between 1 January 2005 and 31 December 2010, as some of the trials might be registered or conducted but may not be completed in the predecided time frame for this research question. After clinical trial completion, the sponsor has to submit the clinical study report within 12 months to the regulatory authorities. On this basis, we decided that 14 months was an adequate period for the sponsor to file a New Drug Application (NDA) in the relevant country. Therefore, we excluded the clinical trials having update information later than 14 month after completion date. We searched <http://www.fda.gov> US Food and Drug Administration, <http://www.ema.europa.eu> European Medicines Agency, <http://www.cdsco.nic.in> Central Drug Standard Control Organization, India (CDSCO) and <http://www.mccza.com> Medicines Control Council (MCC), South Africa along with South African Medicine Price Registry <http://www.mpr.gov.za> for new drug approval in the USA, the EU, India and South Africa, respectively, for the time period from 2006 until 2013.

Database {#s2c}
--------

From each trial, we extracted the following information: title of the trial, sponsor, indication and IMP (Investigational Medicinal Product). From the new product approval database, we extracted the new product approval date. We reviewed the selected sets of trials for a duplicate check on the sponsor, IMP and indication to avoid miscounting the total number of trials potentially being included in the New Drug Approval list. [Figure 1](#BMJOPEN2014007304F1){ref-type="fig"} gives the details of generation of data. Search was repeated by us to validate the correctness of data.

![Clinical trials and NDA approvals in India and South Africa. NDA, New Drug Application.](bmjopen2014007304f01){#BMJOPEN2014007304F1}

Analysis {#s2d}
--------

Data analysis was done on the following determined data sets by the following criteria: not approved in any of the countries/regions; approved in the EU and/or the USA, but not in India and South Africa, respectively; approved in India/South Africa, respectively, and in either the EU and/or the USA.

Results {#s3}
=======

[Figure 1](#BMJOPEN2014007304F1){ref-type="fig"} illustrates the initial generation of data and its subsequent handling for analysis. We screened 1175 trials from <http://www.clinicaltrials.gov> registered in the period from 1 January 2005 to 31 December 2010. Out of 1175 trials, there were 596 and 579 trials for India and South Africa, respectively. Trials with update information later than 14-month after the completion date were eliminated, which resulted in 320 and 302 trials for India and South Africa, respectively. Further clustering clinical trials with the same sponsor and same IND resulted in 224 and 229 clinical trials for India and South Africa, respectively. This formed the basis for our analysis. These clinical trials were screened at the Indian regulatory site (<http://www.cdsco.nic.in>), South African regulatory sites (<http://www.mccza.com> and <http://www.mpr.gov.za>), European Medicines Agency site (<http://www.ema.europa.eu>) and USFDA site (<http://www.fda.gov>) to determine the new drug approval status in respective countries.

[Figure 2](#BMJOPEN2014007304F2){ref-type="fig"} shows the percentage of clinical trials leading to market approval. 59.4% (India) and 39.8% (South Africa) of the multinational clinical trials did not result in NDA approval anywhere -- not in the respective country (India/South Africa) or the EU/USA. It was seen that only 24.5% and 24% clinical trials led to marketing approval in India and South Africa, respectively. It was seen that in 16.1% approval was only available in the EU and/or the USA without parallel approval in India. In case of South Africa, this number was strikingly high, that is, 36.2% trials led to approval in the EU and/or the USA without parallel approval in South Africa.

![Percentage of clinical trials leading to market approval.](bmjopen2014007304f02){#BMJOPEN2014007304F2}

Inequalities were more evident when we focused on the distribution of marketing approval between the EU/USA and India/South Africa as seen in [figure 3](#BMJOPEN2014007304F3){ref-type="fig"}. In 39.6% and 60.1% trials, respectively, for India and South Africa, marketing approval was only received in the EU/USA without approval in India and South Africa, respectively.

![Distribution of marketing approval between the EU/USA and India/South Africa.](bmjopen2014007304f03){#BMJOPEN2014007304F3}

[Table 1](#BMJOPEN2014007304TB1){ref-type="table"} shows the % of clinical trials and % cause specific mortality as per the WHO report[@R8] for India and South Africa. There were a large number of clinical trials for neuropsychiatric conditions (20%), diabetes (19%) and cardiovascular diseases (16%) conducted in India. Diabetes and cardiovascular diseases are listed in the WHO Report as relevant causes for mortality in India with a subsequent country programme to address those diseases.[@R8] For clinical trials conducted in South Africa, neuropsychiatric conditions (22%) and various types of malignancies (14.5%), followed by cardiovascular diseases (12.0%), were the main indications.

###### 

Percentage of clinical trials and % cause specific mortality for India and South Africa

                                      India   South Africa          
  ----------------------------------- ------- -------------- ------ -----
  Musculoskeletal diseases            4       1.7            5      1
  Neoplasm                            13      3.5            14.5   3.2
  Neuropsychiatric conditions         20      11.6           22     5.9
  Cardiovascular diseases             16      12.6           12     7.7
  Diabetes                            19      11.0           15.7   1.8
  Eye diseases                        3       5.4            1.4    3.7
  Digestive diseases                  3       3              8.7    2
  Infectious and parasitic diseases   13      17             9.1    48
  Genitourinary diseases              5       1.1            4.5    1
  Respiratory diseases                4       4.5            7.1    3

Discussion {#s4}
==========

We identified clinical trials conducted from 1 January 2005 to 31 December 2010 and registered on <http://www.clinicaltrials.gov>. Our results reveal that there is a mismatch between the percentage of clinical trials conducted and NDAs in India and South Africa. Globally, a large number of multinational clinical trials (59.4% in India and 39.8% in South Africa) did not result in NDA approval anywhere, that is, in the respective country---India/South Africa or the EU/USA. This is alarming and highlights the problem with clinical success rate (movement of drug from clinical trials to the market).[@R9] This is associated with many factors like trial costs, regulatory framework, trial complexity and patient recruitment issues. Against this background, emerging economies have shown the potential to become global players in the field of clinical research.

After focusing only on the percentage of clinical trials resulting in an NDA, it was clear that for 39.6% and 60.1% trials, respectively, for India and South Africa, marketing approval was only received in the EU/USA without approval in India and South Africa. As regards participation in the eventual benefits, the Declaration of Helsinki offers clear guidance, especially for research conducted in the developing countries.[@R10] The year 2000 version of the Declaration of Helsinki states categorically that at the end of any research study, every subject entered in the project should be assured of the best proven prophylactic, diagnostic and therapeutic methods identified by that study.[@R10] The World Medical Assembly emphasises that medical research is only justified if there is a reasonable likelihood that the populations in which the research is carried out stand to benefit from the results of the research.[@R10] The Indian drug regulatory authorities ask sponsors to confirm that they will market the drug after conducting the trial on the Indian population.[@R11] However, the result of our study clearly shows that this regulation is not followed by sponsors even after they make a commitment on paper with the regulatory authorities of India.

Also, it is very important to have a balance between the research areas and the present need of the respective countries.[@R4] [@R12] Our results show the imbalance between the focused research areas and the disease prevalence of India and South Africa. Similar results have also been reported by Glickman EW that global players are not focusing their research on the priorities of the developing countries.[@R2] A comparison between the cause specific mortality of India and South Africa and the indications of clinical trials conducted revealed only a partial match. There were no clinical trials in the area of maternal and perinatal conditions, nutritional disorders which are the main causes of mortality in India. We would also like to focus on the high number of trials conducted in the areas of neoplasms, neuropsychiatry, musculoskeletal diseases and genitourinary diseases which might not be relevant to the local population in India. For South Africa, the WHO report[@R8] confirms cardiovascular diseases and neoplasms as critical areas in healthcare. However, infectious diseases and, in particular, HIV form by far the area associated with the highest medical need, which are a far less explored indication for clinical trials conducted in South Africa. Even for South Africa there were a high number of clinical trials in the area of neuropsychiatry, musculoskeletal diseases, diabetes and genitourinary diseases which might not be relevant as per the WHO cause specific mortality data to the local population. This highlights the need to refocus on the issue of vulnerability of emerging economies' patient participation in the clinical trial in spite of discussions over the past decade.[@R4] [@R13] [@R14]

Implications for Ethics Committees and investigators {#s4a}
----------------------------------------------------

The National Bioethics Advisory Commission (NBAC)[@R14] in its report recommends that researchers should, before initiation of a research study, endeavour to secure access for all participants to effective treatment after the trial and that the lack of any such arrangements should be justified to a research ethics committee (REC). The report also recommends that researchers should indicate in their proposals how they intend to make the intervention available to participants after the trial if the intervention is proven successful. There is a need to ensure that developing countries are not used as sites for research that is not of relevance to them and thus protect the vulnerable population.[@R4] The Council for International Organizations of the Medical Sciences Guidelines specifically state that all research that is conducted in developing countries and sponsored by developed countries should be of relevance to the developing countries. The relevance of the study to the country is a sure way of ensuring that countries stand to benefit once their citizens participate as subjects in clinical research. In the words of Lang and Siribaddana,[@R4] "the globalisation of trials should not be about running inexpensive trial sites to benefit distant people, but should focus on bringing research to populations who have previously been under-represented in clinical trials and enabling these same communities the benefits from new drugs."

Research Ethics Committees, being the gatekeepers when it comes to health research, have to play an important role of ensuring that the communities and individuals are not exploited in research.[@R12] More often, it is very difficult for a community to voice its concerns due to various reasons including lack of appropriate structures for communication. The ethics committees can therefore serve as the voice of the voiceless communities and individuals in developing countries. The developing countries and institutions need to come to the negotiating table with sponsors since they have a very useful resource in research---human beings who are willing to participate in research. The benefit sharing ensures that the disadvantaged at least benefit in some way from an activity in which they have participated.

Implications for regulators {#s4b}
---------------------------

The pace of clinical research in developing countries is accelerating in India and South Africa. Both these countries are not in a stage to support independent clinical research like western developed countries. They need to be a part of international clinical trials, but this should be without compromising ethics and research benefits sharing. Regulatory authorities from India and South Africa should formulate a regulation making it compulsory to market the new drugs at affordable prices in India and South Africa after conducting clinical trials on the local population. It is very important that clinical research should focus on the most relevant disease of these countries. There should be a provision to blacklist or fine the sponsor if they do not market the new drugs in India or South Africa and market only in the EU/USA.

Conclusion {#s5}
==========

In this paper, we take the view that clinical research is important for developing countries as it offers benefits in terms of knowledge, patient care and business. Sponsors should not exploit the local population for research without offering the benefits of research by making the new drug available in markets of developing countries. Sponsors and investigators should take reasonable efforts, plan before study initiation and discuss with benefits and risk of study with local communities. Clinical research stands on the basic premise of enhancing the present scientific knowledge and, if ethically designed and conducted, it is the most scientific path to invent new treatment modalities. Therefore, the benefits of this ethical research should be extended post trial not only to study subjects but to the entire host community.

In general, the goal of clinical research is to support the drug development and availability of new medicines while ensuring that research is always balanced to the local need of the country. There is a need not only to have stringent regulations, but also to monitor its follow-up. We feel that institutional review boards, investigators and patient groups, along with regulatory authorities, have a clear role in ensuring market availability of drugs after research and thus bridging the gap between the developing and developed nations.
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